Publications
272
Citations
2,535
Est. group size
~2
Recurring co-author estimate
Active years
25
Publishing since 2002
Laura J. Myers works in clinical and health-services medicine, with research spanning stroke care delivery, quality-improvement programs in healthcare settings, and preclinical studies on muscle wasting in cancer. The work appears to combine applied health-policy and program-evaluation studies with some laboratory-based biomedical research.
Publication output has been steady over the past decade, averaging around 21 papers per year in recent years with a notable peak in 2023.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- EVALUATION OF A QUALITY IMPROVEMENT PROGRAM OPTIMIZING SCIG IN HOME INFUSION PRIMARY IMMUNODEFICIENCY PATIENTS
Annals of Allergy Asthma & Immunology · 2025
- Realising agency: insights from participatory research with learners in a South African sexual and reproductive health programme
Frontiers in Public Health · 2024
- Reconsidering the Saffir-Simpson Scale: A Qualitative Investigation of Public Understanding and Alternative Frameworks
Hurricane Risk/Hurricane risk · 2024
- Abstract 80: Predictors of Door-to-Needle Time in the Veterans Health Administration National Telestroke Program
Stroke · 2024
- Supplementary Figure 6 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 4 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 3 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure Legends from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 2 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 5 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 1 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure Legends from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 5 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 1 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Supplementary Figure 2 from Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
2023
- Stroke×19
- PMC×9
- Neurology×8
- JAMA Network Open×7
- Journal of General Internal Medicine×6
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile